Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Gri Bio Inc (GRI)

Gri Bio Inc (GRI)
0.4352 -0.0949 (-17.90%) 02/20/25 [NASDAQ]
0.4323 x 2 0.4600 x 17
Realtime by (Cboe BZX)
0.4323 x 2 0.4600 x 17
Realtime 0.4600 +0.0248 (-) 16:05 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4045
Day High
0.4679
Open 0.4045
Previous Close 0.5301 0.5301
Volume 426,463 426,463
Avg Vol 170,203 170,203
Stochastic %K 32.14% 32.14%
Weighted Alpha -91.96 -91.96
5-Day Change -0.1101 (-20.02%) -0.1101 (-20.02%)
52-Week Range 0.3015 - 13.6500 0.3015 - 13.6500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,736
  • Shares Outstanding, K 8,933
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,040 K
  • EBIT $ -7 M
  • EBITDA $ -5 M
  • 60-Month Beta -2.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.57
  • Most Recent Earnings $-0.67 on 11/14/24
  • Next Earnings Date 03/27/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4045 +8.75%
on 02/20/25
Period Open: 0.7203
0.7400 -40.55%
on 01/21/25
-0.2804 (-38.93%)
since 01/17/25
3-Month
0.4045 +8.75%
on 02/20/25
Period Open: 0.6390
0.9950 -55.79%
on 12/11/24
-0.1991 (-31.16%)
since 11/20/24
52-Week
0.3015 +45.90%
on 10/01/24
Period Open: 12.6100
13.6500 -96.78%
on 02/22/24
-12.1701 (-96.51%)
since 02/20/24

Most Recent Stories

More News
GRI Bio Announces Reverse Stock Split

GRI : 0.4352 (-17.90%)
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI : 0.4352 (-17.90%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.0550 (-0.47%)
AREC : 0.5743 (-2.25%)
OTLK : 1.6400 (-3.24%)
AMIX : 2.93 (+2.09%)
CNSP : 0.0750 (-10.50%)
PALI : 0.9800 (+0.37%)
NVNO : 3.82 (+6.41%)
HURA : 3.30 (+3.77%)
GRI : 0.4352 (-17.90%)
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI : 0.4352 (-17.90%)
GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI : 0.4352 (-17.90%)
GRI Bio Presents Positive Preclinical Data on GRI-0621 for Treating Pulmonary Fibrosis at AFDD Summit

GRI Bio presented preclinical data on GRI-0621, showing its potential to treat idiopathic pulmonary fibrosis by inhibiting iNKT cell activity.Quiver AI SummaryGRI Bio, Inc. presented positive preclinical...

GRI : 0.4352 (-17.90%)
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI : 0.4352 (-17.90%)
GRI Bio, Inc. Reports $13.9 Million in Gross Proceeds and Provides Update on GRI-0621 Phase 2a Study for IPF Treatment

GRI Bio raised $13.9 million, extending its cash runway for GRI-0621's Phase 2a study in idiopathic pulmonary fibrosis.Quiver AI SummaryGRI Bio, Inc. announced it has raised $13.9 million in gross proceeds...

GRI : 0.4352 (-17.90%)
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI : 0.4352 (-17.90%)
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI : 0.4352 (-17.90%)

Business Summary

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

See More

Key Turning Points

3rd Resistance Point 0.6434
2nd Resistance Point 0.6167
1st Resistance Point 0.5734
Last Price 0.4352
1st Support Level 0.5034
2nd Support Level 0.4767
3rd Support Level 0.4334

See More

52-Week High 13.6500
Fibonacci 61.8% 8.5509
Fibonacci 50% 6.9757
Fibonacci 38.2% 5.4006
Last Price 0.4352
52-Week Low 0.3015

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements